1. Home
  2. SCLX vs TENX Comparison

SCLX vs TENX Comparison

Compare SCLX & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.82

Market Cap

52.9M

Sector

Health Care

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$14.43

Market Cap

56.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
TENX
Founded
2011
1967
Country
United States
United States
Employees
30
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
52.9M
56.2M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
SCLX
TENX
Price
$6.82
$14.43
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
41.1K
476.2K
Earning Date
04-10-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$122.52
N/A
Revenue Next Year
$186.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.95
$5.34
52 Week High
$34.27
$18.38

Technical Indicators

Market Signals
Indicator
SCLX
TENX
Relative Strength Index (RSI) 45.53 51.98
Support Level $6.20 $13.16
Resistance Level $7.77 $16.61
Average True Range (ATR) 0.72 0.88
MACD 0.10 -0.11
Stochastic Oscillator 71.43 60.00

Price Performance

Historical Comparison
SCLX
TENX

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.

Share on Social Networks: